New stent technologies

Yukio Ozaki, A. G. Violaris, P. W. Serruys

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Coronary stents were developed to overcome the two main limitations of balloon angioplasty, acute occlusion and long-term restenosis. Coronary stents can tack back intimal flaps and seal the dissected vessel wall, thereby treating acute or threatened vessel closure after unsuccessful balloon angioplasty. After successful balloon angioplasty, stents can prevent late vessel remodeling (chronic vessel recoil) by mechanically enforcing the vessel wall and resetting the vessel size, resulting in a low incidence of restenosis. All currently available stents are composed of metal, and the long-term effects of their implantation in the coronary arteries are still not clear. Because of the metallic surface, they are also thrombogenic; therefore, rigorous antiplatelet or anticoagulant therapy is theoretically required. Furthermore, they have an imperfect compromise between scaffolding properties and flexibility, resulting in an unfavorable interaction between stents and unstable or thrombus-laden plaque. Finally, they still induce substantial intimal hyperplasia that may result in restenosis. Future stents can be made less thrombogenic by modifying the metallic surface or coating it with an antithrombotic agent or a membrane eluting an antithrombotic drug. The unfavorable interaction with the unstable plaque and the thrombus burden can be overcome by covering the stent with a biological conduit, such as a vein, or a biodegradable material that can be endogenous, such as fibrin, or exogenous, such as a polymer. Finally, the problem of persisting induction of intimal hyperplasia may be overcome with the use of either a radioactive stent or a stent eluting an antiproliferative drug.

Original languageEnglish
Pages (from-to)129-140
Number of pages12
JournalProgress in Cardiovascular Diseases
Volume39
Issue number2
DOIs
Publication statusPublished - 01-01-1996
Externally publishedYes

Fingerprint

Stents
Technology
Tunica Intima
Balloon Angioplasty
Hyperplasia
Thrombosis
Drug-Eluting Stents
Fibrinolytic Agents
Fibrin
Anticoagulants
Veins
Coronary Vessels
Polymers
Metals
Membranes
Incidence
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Ozaki, Yukio ; Violaris, A. G. ; Serruys, P. W. / New stent technologies. In: Progress in Cardiovascular Diseases. 1996 ; Vol. 39, No. 2. pp. 129-140.
@article{f72683e3ea654e4f8045216235e99559,
title = "New stent technologies",
abstract = "Coronary stents were developed to overcome the two main limitations of balloon angioplasty, acute occlusion and long-term restenosis. Coronary stents can tack back intimal flaps and seal the dissected vessel wall, thereby treating acute or threatened vessel closure after unsuccessful balloon angioplasty. After successful balloon angioplasty, stents can prevent late vessel remodeling (chronic vessel recoil) by mechanically enforcing the vessel wall and resetting the vessel size, resulting in a low incidence of restenosis. All currently available stents are composed of metal, and the long-term effects of their implantation in the coronary arteries are still not clear. Because of the metallic surface, they are also thrombogenic; therefore, rigorous antiplatelet or anticoagulant therapy is theoretically required. Furthermore, they have an imperfect compromise between scaffolding properties and flexibility, resulting in an unfavorable interaction between stents and unstable or thrombus-laden plaque. Finally, they still induce substantial intimal hyperplasia that may result in restenosis. Future stents can be made less thrombogenic by modifying the metallic surface or coating it with an antithrombotic agent or a membrane eluting an antithrombotic drug. The unfavorable interaction with the unstable plaque and the thrombus burden can be overcome by covering the stent with a biological conduit, such as a vein, or a biodegradable material that can be endogenous, such as fibrin, or exogenous, such as a polymer. Finally, the problem of persisting induction of intimal hyperplasia may be overcome with the use of either a radioactive stent or a stent eluting an antiproliferative drug.",
author = "Yukio Ozaki and Violaris, {A. G.} and Serruys, {P. W.}",
year = "1996",
month = "1",
day = "1",
doi = "10.1016/S0033-0620(96)80022-3",
language = "English",
volume = "39",
pages = "129--140",
journal = "Progress in Cardiovascular Diseases",
issn = "0033-0620",
publisher = "W.B. Saunders Ltd",
number = "2",

}

New stent technologies. / Ozaki, Yukio; Violaris, A. G.; Serruys, P. W.

In: Progress in Cardiovascular Diseases, Vol. 39, No. 2, 01.01.1996, p. 129-140.

Research output: Contribution to journalArticle

TY - JOUR

T1 - New stent technologies

AU - Ozaki, Yukio

AU - Violaris, A. G.

AU - Serruys, P. W.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Coronary stents were developed to overcome the two main limitations of balloon angioplasty, acute occlusion and long-term restenosis. Coronary stents can tack back intimal flaps and seal the dissected vessel wall, thereby treating acute or threatened vessel closure after unsuccessful balloon angioplasty. After successful balloon angioplasty, stents can prevent late vessel remodeling (chronic vessel recoil) by mechanically enforcing the vessel wall and resetting the vessel size, resulting in a low incidence of restenosis. All currently available stents are composed of metal, and the long-term effects of their implantation in the coronary arteries are still not clear. Because of the metallic surface, they are also thrombogenic; therefore, rigorous antiplatelet or anticoagulant therapy is theoretically required. Furthermore, they have an imperfect compromise between scaffolding properties and flexibility, resulting in an unfavorable interaction between stents and unstable or thrombus-laden plaque. Finally, they still induce substantial intimal hyperplasia that may result in restenosis. Future stents can be made less thrombogenic by modifying the metallic surface or coating it with an antithrombotic agent or a membrane eluting an antithrombotic drug. The unfavorable interaction with the unstable plaque and the thrombus burden can be overcome by covering the stent with a biological conduit, such as a vein, or a biodegradable material that can be endogenous, such as fibrin, or exogenous, such as a polymer. Finally, the problem of persisting induction of intimal hyperplasia may be overcome with the use of either a radioactive stent or a stent eluting an antiproliferative drug.

AB - Coronary stents were developed to overcome the two main limitations of balloon angioplasty, acute occlusion and long-term restenosis. Coronary stents can tack back intimal flaps and seal the dissected vessel wall, thereby treating acute or threatened vessel closure after unsuccessful balloon angioplasty. After successful balloon angioplasty, stents can prevent late vessel remodeling (chronic vessel recoil) by mechanically enforcing the vessel wall and resetting the vessel size, resulting in a low incidence of restenosis. All currently available stents are composed of metal, and the long-term effects of their implantation in the coronary arteries are still not clear. Because of the metallic surface, they are also thrombogenic; therefore, rigorous antiplatelet or anticoagulant therapy is theoretically required. Furthermore, they have an imperfect compromise between scaffolding properties and flexibility, resulting in an unfavorable interaction between stents and unstable or thrombus-laden plaque. Finally, they still induce substantial intimal hyperplasia that may result in restenosis. Future stents can be made less thrombogenic by modifying the metallic surface or coating it with an antithrombotic agent or a membrane eluting an antithrombotic drug. The unfavorable interaction with the unstable plaque and the thrombus burden can be overcome by covering the stent with a biological conduit, such as a vein, or a biodegradable material that can be endogenous, such as fibrin, or exogenous, such as a polymer. Finally, the problem of persisting induction of intimal hyperplasia may be overcome with the use of either a radioactive stent or a stent eluting an antiproliferative drug.

UR - http://www.scopus.com/inward/record.url?scp=0029798810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029798810&partnerID=8YFLogxK

U2 - 10.1016/S0033-0620(96)80022-3

DO - 10.1016/S0033-0620(96)80022-3

M3 - Article

VL - 39

SP - 129

EP - 140

JO - Progress in Cardiovascular Diseases

JF - Progress in Cardiovascular Diseases

SN - 0033-0620

IS - 2

ER -